Why the study?
To explore the expression characteristics, diagnostic efficacy, and correlation with glucose metabolism disorders of circRNA CDR1as in patients with diabetes mellitus complicated by NAFLD.
Does serum circRNA CDR1as level accurately diagnose NAFLD and correlate with glucose metabolism in patients with diabetes mellitus?
Population
74 DM patients complicated by NAFLD and 71 patients with uncomplicated DM
Comparison
DM patients complicated by NAFLD vs uncomplicated DM
Key result
Serum circRNA CDR1as demonstrated a diagnostic AUC of 0.781 for identifying non-alcoholic fatty liver disease in patients with diabetes mellitus, with 64.86% sensitivity and 80.28% specificity.
Authors
Loading...
Should not yet alter NAFLD screening in diabetes; leaves open prospective validation of circRNA CDR1as as a biomarker.
Case-Control (n=145)
No
Does serum circRNA CDR1as level accurately diagnose NAFLD and correlate with glucose metabolism in patients with diabetes mellitus?
Effect estimate: AUC 0.781
p-value: p=<0.05
Serum circRNA CDR1as is a promising non-invasive biomarker for diagnosing NAFLD and stratifying disease severity in patients with diabetes mellitus.
Zhang et al. (2025) conducted a case-control in Diabetes mellitus complicated by non-alcoholic fatty liver disease (NAFLD) (n=145). Serum circRNA CDR1as vs. Uncomplicated diabetes mellitus was evaluated on Diagnostic efficacy for NAFLD (AUC 0.781, p=<0.05). Serum circRNA CDR1as demonstrated a diagnostic AUC of 0.781 for identifying non-alcoholic fatty liver disease in patients with diabetes mellitus, with 64.86% sensitivity and 80.28% specificity.